ClinicalTrials.gg
CompletedNCT03170388Updated Nov 10, 2021Results posted

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

A Phase 2 interventional study of IDP-126 Gel and IDP-126 Component A in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 34 sites in 2 countries. Open to participants aged 9 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-11-10.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
741
Allocation
Randomized
Ages
9 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..

Enrollment
9th of 35
741 · median 247
Started
2017
with 2 others
Phase 2
10 of 36
none open now
Registered
28th of 36
by date

Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 9th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2017, is one of 10 in phase 2, and was the 28th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Acne Vulgaris by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

Read the detailed description

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 9 years of age and older.
  2. Written and verbal must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
  3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.
  4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20, but no more than 100.
  5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 30, but no more than 150.
  6. Subjects with 2 or fewer facial nodules

Exclusion criteria

Exclusion Criteria:

  1. Use of an drug or device within 30 days of enrollment or participation in a research study concurrent with this study.
  2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, rosacea, gram negative folliculitis, dermatitis, eczema.
  3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
  4. Subjects with a facial beard or mustache that could interfere with the study assessments.
  5. Subjects with more than 2 facial nodules.
  6. Evidence or history of cosmetic-related acne.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
741 participants (actual)

Study arms

  • Experimental
    IDP-126 Gel

    Gel

    Drug: IDP-126 Gel

  • Active comparator
    IDP-126 Component A

    Component A

    Drug: IDP-126 Component A

  • Active comparator
    IDP-126 Component B

    Component B

    Drug: IDP-126 Component B

  • Active comparator
    IDP-126 Component C

    Component C

    Drug: IDP-126 Component C

  • Placebo comparator
    IDP-126 Vehicle Gel

    Vehicle Gel

    Drug: IDP-126 Vehicle Gel

Interventions

06

What researchers measure

Primary outcomes

  1. Inflammatory Lesion Counts

    Absolute change from Baseline to Week 12 in mean inflammatory lesion counts

    Time frame: Baseline to Week 12

  2. Non-inflammatory Lesion Counts

    Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts

    Time frame: Baseline to Week 12

  3. Percentage of Participants With Success on the Evaluator's Global Severity Score

    Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Inflammatory Lesion Count Changes at Week 2, 4, and 8

    Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts

    Time frame: Baseline to Week 2, 4, 8

  2. Non-inflammatory Lesion Count Changes at Week 2, 4, and 8

    Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts

    Time frame: Baseline to Week 2, 4, 8

  3. Inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8

    Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts

    Time frame: Baseline to Week 2, 4, 8

  4. Non-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8

    Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts

    Time frame: Baseline to Week 2, 4, 8

  5. Percentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8

    Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

    Time frame: Baseline to Week 2, 4, and 8

  6. Percentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8

    Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

    Time frame: Baseline to Week 2, 4, and 8

07

Results

Posted Nov 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Started147150146150148
Completed125132133132127
Not completed2218131821

Outcome measures

PrimaryInflammatory Lesion Counts

Absolute change from Baseline to Week 12 in mean inflammatory lesion counts

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · lesions
Inflammatory Lesion Counts
lesionsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Inflammatory Lesion Counts-29.9 ± 11.86-26.7 ± 11.74-24.8 ± 11.71-26.8 ± 11.69-19.6 ± 12.12
PrimaryNon-inflammatory Lesion Counts

Absolute change from Baseline to Week 12 in mean non-inflammatory lesion counts

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · lesions
Non-inflammatory Lesion Counts
lesionsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Non-inflammatory Lesion Counts-35.5 ± 16.25-29.9 ± 16.40-27.8 ± 15.97-30.0 ± 16.40-21.8 ± 16.58
PrimaryPercentage of Participants With Success on the Evaluator's Global Severity Score

Success was defined as at least a two grade reduction and clear or almost clear at Week 12. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Success on the Evaluator's Global Severity Score
percentage of participantsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Percentage of Participants With Success on the Evaluator's Global Severity Score52.527.830.530.38.1
SecondaryInflammatory Lesion Count Changes at Week 2, 4, and 8

Absolute change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts

Time frame:
Baseline to Week 2, 4, 8
Reported as:
Mean · lesions
Inflammatory Lesion Count Changes at Week 2, 4, and 8
lesionsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Week 2-14.0 ± 11.62-11.8 ± 10.80-13.8 ± 10.50-13.4 ± 10.76-9.2 ± 9.58
Week 4-21.0 ± 10.33-17.1 ± 12.07-18.8 ± 12.05-17.7 ± 11.49-14.8 ± 10.26
Week 8-25.8 ± 11.97-23.0 ± 11.69-23.1 ± 13.95-22.8 ± 9.86-17.5 ± 10.86
SecondaryNon-inflammatory Lesion Count Changes at Week 2, 4, and 8

Absolute change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts

Time frame:
Baseline to Week 2, 4, 8
Reported as:
Mean · lesions
Non-inflammatory Lesion Count Changes at Week 2, 4, and 8
lesionsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Week 2-12.9 ± 12.90-11.0 ± 14.31-11.2 ± 10.97-11.3 ± 14.02-9.2 ± 11.94
Week 4-21.4 ± 14.33-18.6 ± 13.74-15.8 ± 13.77-18.0 ± 14.35-13.7 ± 11.78
Week 8-30.5 ± 15.95-25.1 ± 15.43-21.7 ± 16.08-26.8 ± 14.68-17.6 ± 15.29
SecondaryInflammatory Lesion Count Percentage Changes at Week 2, 4, and 8

Percentage change from Baseline to Week 2, 4, and 8 in mean inflammatory lesion counts

Time frame:
Baseline to Week 2, 4, 8
Reported as:
Mean · percentage change
Inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8
percentage changeIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Week 2-35.89 ± 29.073-30.27 ± 26.417-35.10 ± 26.442-35.23 ± 26.926-24.18 ± 26.000
Week 4-54.42 ± 22.683-44.37 ± 28.511-47.55 ± 28.040-46.32 ± 27.664-39.95 ± 27.304
Week 8-66.07 ± 22.239-59.07 ± 25.573-59.55 ± 31.990-60.10 ± 23.863-46.61 ± 27.495
SecondaryNon-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8

Percentage change from Baseline to Week 2, 4, and 8 in mean non-inflammatory lesion counts

Time frame:
Baseline to Week 2, 4, 8
Reported as:
Mean · percentage change
Non-inflammatory Lesion Count Percentage Changes at Week 2, 4, and 8
percentage changeIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Week 2-27.07 ± 26.440-23.39 ± 30.433-23.72 ± 22.845-24.91 ± 28.698-19.68 ± 23.194
Week 4-43.17 ± 27.162-39.28 ± 26.422-33.84 ± 29.592-38.14 ± 27.765-29.53 ± 26.025
Week 8-60.05 ± 25.164-52.76 ± 27.916-47.29 ± 32.982-54.17 ± 26.530-37.84 ± 29.933
SecondaryPercentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8

Success was defined as at least a two grade reduction and clear or almost clear at the visit. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

Time frame:
Baseline to Week 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants With Success on the Evaluator's Global Severity Score at Weeks 2, 4, and 8
percentage of participantsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Week 21.491.350.712.680.00
Week 48.176.772.794.271.36
Week 820.4615.9715.2615.753.51
SecondaryPercentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8

Two grade success was defined as at least a two grade reduction. The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

Time frame:
Baseline to Week 2, 4, and 8
Reported as:
Number · percentage of participants
Percentage of Participants With Two Grade Success on the Evaluator's Global Severity Score - at Weeks 2, 4, and 8
percentage of participantsIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Week 22.952.781.455.441.36
Week 411.4610.535.838.512.12
Week 828.7422.7919.9720.664.43

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDP-126 Gel0/141 (0%)1/141 (0.7%)30/141 (21.3%)
IDP-126 Component A0/146 (0%)0/146 (0%)29/146 (19.9%)
IDP-126 Component B0/144 (0%)0/144 (0%)6/144 (4.2%)
IDP-126 Component C0/148 (0%)3/148 (2%)19/148 (12.8%)
IDP-126 Vehicle Gel0/146 (0%)0/146 (0%)7/146 (4.8%)
Most frequent serious events
Most frequent serious events
EventIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Sickle cell anemia with crisisBlood and lymphatic system disorders1/1410/1460/1440/1480/146
EnteritisGastrointestinal disorders0/1410/1460/1441/1480/146
HyperbilirubinemiaHepatobiliary disorders0/1410/1460/1441/1480/146
Abortion inducedSurgical and medical procedures0/1410/1460/1441/1480/146
Most frequent other events
Most frequent other events
EventIDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle Gel
Application Site PainGeneral disorders11/14116/1461/1445/1481/146
Viral Upper Respiratory Tract InfectionInfections and infestations10/1415/1463/1445/1485/146
Application Site DrynessGeneral disorders9/1418/1462/1449/1481/146

Baseline characteristics

One participant in the IDP-126 Gel group did not receive study medication and thus is not included in the demography population.

Age, Continuous
Age, Continuous(years)IDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle GelTotal
Median17 (11 to 46)17 (10 to 60)17 (10 to 45)17 (11 to 50)17 (11 to 47)17 (10 to 60)
Sex: Female, Male
Sex: Female, Male(Participants)IDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle GelTotal
Female9486919389453
Male5264555759287
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle GelTotal
American Indian or Alaska Native111126
Asian106891750
Native Hawaiian or Other Pacific Islander240107
Black or African American2426302026126
White9810910110995512
More than one race114610839
Unknown or Not Reported000000
Baseline Evaluator's Global Severity Score
Baseline Evaluator's Global Severity Score(Participants)IDP-126 GelIDP-126 Component AIDP-126 Component BIDP-126 Component CIDP-126 Vehicle GelTotal
Moderate124119124129127623
Severe2231222121117
08

Study locations

34 sites
  • Valeant Site 02
    Hot Springs, Arkansas 71913, United States
  • Valeant Site 07
    Fremont, California 94538, United States
  • Valeant Site 08
    Sacramento, California 95819, United States
  • Valeant Site 09
    Denver, Colorado 80220, United States
  • Valeant Site 11
    Boynton Beach, Florida 33437, United States
  • Valeant Site 13
    North Miami Beach, Florida 33162, United States
  • Valeant Site 12
    Sanford, Florida 32771, United States
  • Valeant Site 10
    West Palm Beach, Florida 33401, United States
  • Valeant Site 15
    Marietta, Georgia 30060, United States
  • Valeant Site 14
    Snellville, Georgia 30078, United States
  • Valeant Site 16
    Boise, Idaho 83704, United States
  • Valeant Site 17
    Overland Park, Kansas 66215, United States
  • Valeant Site 18
    Louisville, Kentucky 40217, United States
  • Valeant Site 19
    Louisville, Kentucky 40241, United States
  • valeant Site 21
    Glenn Dale, Maryland 20769, United States
  • Valeant Site 20
    Needham, Massachusetts 02492, United States
  • Valeant Site 22
    Detroit, Michigan 48202, United States
  • Valeant Site 24
    Morristown, New Jersey 07960, United States
  • Valeant Site 25
    Albuquerque, New Mexico 87106, United States
  • Valeant Site 27
    New York, New York 10022, United States
  • Valeant Site 26
    New York, New York 10075, United States
  • Valeant Site 23
    High Point, North Carolina 27262, United States
  • Valeant Site 28
    Gresham, Oregon 97030, United States
  • Valeant Site 30
    Johnston, Rhode Island 02919, United States
  • Valeant Site 31
    Nashville, Tennessee 37215, United States
  • Valeant Site 32
    Austin, Texas 78759, United States
  • Valeant Site 33
    Pflugerville, Texas 78660, United States
  • valeant Site 34
    San Antonio, Texas 78213, United States
  • Valeant Site 35
    Norfolk, Virginia 23502, United States
  • Valeant Site 01
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Valeant Site 05
    Barrie, Ontario L4M7G1, Canada
  • Valeant Site 06
    Oakville, Ontario L6J7W5, Canada
  • Valeant Site 04
    Peterborough, Ontario K9J5K2, Canada
  • Valeant Site 03
    Waterloo, Ontario N2J1C4, Canada
09

References and documents

Publications

  • Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21. PubMed 34674160 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Apr 2019, 18 months.

Results were first posted in Nov 2021, 2 years 6 months after primary completion. A results delay was requested in Oct 2019.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 18 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2017
First posted
May 31, 2017
StartActual
Oct 5, 2017
Primary completionActual
Apr 23, 2019
CompletionActual
Apr 23, 2019
Results delay requested
Oct 21, 2019
Results first posted
Nov 10, 2021
Last update
Nov 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03170388
Responsible party
Sponsor
First posted
May 31, 2017
Start date
Oct 5, 2017
Primary completion
Apr 23, 2019
Completion
Apr 23, 2019
Results posted
Nov 10, 2021
Last update
Nov 10, 2021

Study contacts

Anya Loncaric
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDP-126

Start the discussion